Cargando…

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is overexpressed in 20–30% of breast cancers and is associated with poor prognosis and worse overall patient survival. Most women with HER2-positive breast cancer receive neoadjuvant chemotherapy plus HER2-targeted therapies. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Najjar, Mariana K., Manore, Sara G., Regua, Angelina T., Lo, Hui-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691220/ https://www.ncbi.nlm.nih.gov/pubmed/36360302 http://dx.doi.org/10.3390/genes13112065

Ejemplares similares

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Tumor Suppressor Candidate 2 (TUSC2): Discovery, Functions, and Cancer Therapy
por: Arrigo, Austin, et al.
Publicado: (2023)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

54. tGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES
por: Doheny, Daniel, et al.
Publicado: (2020)

TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers
por: Regua, Angelina T., et al.
Publicado: (2021)

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
por: Escrivá-de-Romaní, Santiago, et al.
Publicado: (2023)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
por: Ferraro, Emanuela, et al.
Publicado: (2021)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
por: Chiang, Zu-Chian, et al.
Publicado: (2020)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

BSCI-14. tGLI1 is an actionable therapeutic target in breast cancer brain metastases
por: Doheny, Daniel, et al.
Publicado: (2021)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer
por: Dai, Lei-Jie, et al.
Publicado: (2023)

Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy
por: Marcinkowska, Monika, et al.
Publicado: (2019)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
por: Rainone, Michael, et al.
Publicado: (2023)

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
por: Liang, Keying, et al.
Publicado: (2021)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2022)

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
por: Guidi, Lorenzo, et al.
Publicado: (2023)

An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
por: Shin, Seol Hwa, et al.
Publicado: (2021)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
por: Manore, Sara G., et al.
Publicado: (2022)

Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells
por: Abedin, Muhammad Raisul, et al.
Publicado: (2021)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy
por: Liu, Shurong, et al.
Publicado: (2023)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis
por: Doheny, Daniel, et al.
Publicado: (2020)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
por: Jeong, Hwa Yeon, et al.
Publicado: (2020)

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates
por: Heater, Natalie K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vb25osp677a51o9v3uadsb2stt